2009
DOI: 10.1016/j.apradiso.2009.02.011
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of patients with hepatocellular carcinomas using [11C]acetate and [18F]FDG PET/CT: A preliminary study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
36
0
2

Year Published

2010
2010
2022
2022

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 48 publications
(40 citation statements)
references
References 8 publications
2
36
0
2
Order By: Relevance
“…b A left femoral bone metastasis that shows high 18 F-FDG avidity but minimal 11 C-Act uptake upregulated. In humans, previous studies have established the value of 11 C-Act PET for detecting primary and metastatic HCC [17][18][19][20]26] with sensitivities up to 87% in the liver and 77% for metastatic disease (Table 2). Although 11 C-Act PET appears to be one of the most sensitive modalities for detecting HCC and its metastases, studies have shown a complementary relationship between 18 F-FDG and 11 C-Act imaging in HCC, whereby 18 F-FDG PET is often positive in the few patients who are 11 C-Actnegative, with 83% of primary tumours and 86% of metastases being detected in one study by the dual tracer technique [18] and in a further study 98% of metastatic lesions were detected by the dual tracer technique [19] (Figs.…”
Section: C-act Petmentioning
confidence: 98%
See 1 more Smart Citation
“…b A left femoral bone metastasis that shows high 18 F-FDG avidity but minimal 11 C-Act uptake upregulated. In humans, previous studies have established the value of 11 C-Act PET for detecting primary and metastatic HCC [17][18][19][20]26] with sensitivities up to 87% in the liver and 77% for metastatic disease (Table 2). Although 11 C-Act PET appears to be one of the most sensitive modalities for detecting HCC and its metastases, studies have shown a complementary relationship between 18 F-FDG and 11 C-Act imaging in HCC, whereby 18 F-FDG PET is often positive in the few patients who are 11 C-Actnegative, with 83% of primary tumours and 86% of metastases being detected in one study by the dual tracer technique [18] and in a further study 98% of metastatic lesions were detected by the dual tracer technique [19] (Figs.…”
Section: C-act Petmentioning
confidence: 98%
“…The relatively poor sensitivity compared to the use of 18 F-FDG PET in other malignant tumours is probably related to enhanced glucose-6-phosphatase activity in the more differentiated tumours allowing dephosphorylation of 18 F-FDG-6-PO 4 which is therefore not trapped in the cell, resulting in poor tumourto-background activity ratios [11][12][13][14][15][16][17][18][19][20]. However, 18 F-FDG accumulation appears to occur in the more undifferentiated tumours and so there remains a potential role for this tracer in a subset of tumours ( Fig.…”
Section: F-fdg Petmentioning
confidence: 99%
“…In the past few years, dual-tracer PET/CT with 11 C-acetate ( 11 C-ACT) and 18 F-FDG has been found to be useful in the evaluation of primary and metastatic HCC disease (15)(16)(17). Because these 2 tracers are biochemical probes of HCCs and are complementary to each other, according to tumor cellular differentiation, they can not only maximize sensitivity for the detection of malignant lesions but also identify tumors with better differentiation and better prognosis (18).…”
mentioning
confidence: 99%
“…Compte tenu des performances modérées de la TEP-FDG pour la détection du CHC (50-70 %) en particulier des CHC bien différenciés, d'autres traceurs TEP ont été proposés, notamment l'acétate-(11C) traceur de la synthèse des acides gras [9,10,12]. La TEP à l'acétate-(11C) montrait une sensibilité pour le diagnostic de CHC de 87 %, Coupes axiales en TEP-FDG pour bilan d'extension initial d'un carcinome hépatocellulaire survenu chez un homme de 78 ans : la TEP-FDG retrouvait des anomalies au niveau hépatique correspondant à la lésion primitive ainsi qu'au niveau osseux évoquant une maladie métastatique permettant en particulier la détec-tion des CHC bien différenciés, très supérieure à celle de la TEP-FDG évaluée à 47 % [11].…”
Section: Autres Radiopharmaceutiques En Tep Dans Le Chcunclassified